Generated by Meeveem AI
"A muscle focused biopharmaceutical company developing treatments for cardiovascular disease"
Cytokinetics discovers, develops, and commercialises medicines that directly impact muscle mechanics. As a leader in muscle biology for over 25 years, the company creates small molecule muscle activators and inhibitors to treat debilitating diseases characterised by compromised muscle function, including heart failure, hypertrophic cardiomyopathy, and neuromuscular conditions. It received its first FDA approval in 2025. Every medicine Cytokinetics develops aims to preserve and extend independence for people with cardiovascular and neuromuscular muscle dysfunction. The company builds specialty treatment options through rigorous clinical development, having completed pivotal Phase 3 trials. Patients are the driving force behind the science.
673
Team Members
1998
Founded
Biotechnology
Sector
Hybrid
Work Environment
A world where people living with cardiovascular and neuromuscular diseases achieve extended healthspan and independence through medicines that restore muscle function and transform daily life.
At Cytokinetics, our mission is to develop new medicines that may improve outcomes for those living with debilitating diseases of cardiovascular and neuromuscular muscle dysfunction.